124 related articles for article (PubMed ID: 24692710)
1. Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines.
Nitsch E; Mina S; Brammer I; Pace A; Schuch G; Bokemeyer C; Zander A; Kröger N; Ayuk F
Anticancer Res; 2014 Apr; 34(4):1779-84. PubMed ID: 24692710
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
[TBL] [Abstract][Full Text] [Related]
3. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
Giovannetti E; Mey V; Danesi R; Mosca I; Del Tacca M
Clin Cancer Res; 2004 May; 10(9):2936-43. PubMed ID: 15131028
[TBL] [Abstract][Full Text] [Related]
4. 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer.
Eisenberg DP; Adusumilli PS; Hendershott KJ; Yu Z; Mullerad M; Chan MK; Chou TC; Fong Y
J Gastrointest Surg; 2005 Nov; 9(8):1068-77; discussion 1077-9. PubMed ID: 16269377
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients.
Corrie PG; Shaw J; Spanswick VJ; Sehmbi R; Jonson A; Mayer A; Bulusu R; Hartley JA; Cree IA
Br J Cancer; 2005 Jun; 92(11):1997-2003. PubMed ID: 15886706
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effects of photodynamic therapy with HPPH and gemcitabine in pancreatic cancer cell lines.
Sun G; Anderson MA; Gorospe EC; Leggett CL; Lutzke LS; Wong Kee Song LM; Levy M; Wang KK
Lasers Surg Med; 2012 Nov; 44(9):755-61. PubMed ID: 23018618
[TBL] [Abstract][Full Text] [Related]
7. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
Damaraju VL; Bouffard DY; Wong CK; Clarke ML; Mackey JR; Leblond L; Cass CE; Grey M; Gourdeau H
BMC Cancer; 2007 Jul; 7():121. PubMed ID: 17608948
[TBL] [Abstract][Full Text] [Related]
8. [In vitro evaluation of potentially effective gemcitabine combination therapy for exocrine pancreatic carcinoma].
Kreil A; Bauer J; Scheithauer W
Acta Med Austriaca; 1999; 26(3):93-100. PubMed ID: 10520377
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of deuterium oxide and gemcitabine in human pancreatic cancer cell lines.
Bader Y; Hartmann J; Horvath Z; Saiko P; Grusch M; Madlener S; Maier S; Oehler L; Fritzer-Szekeres M; Heller N; Alken RG; Krupitza G; Szekeres T
Cancer Lett; 2008 Feb; 259(2):231-9. PubMed ID: 18023527
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of gemcitabine by Turmeric Force in pancreatic cancer cell lines.
Ramachandran C; Resek AP; Escalon E; Aviram A; Melnick SJ
Oncol Rep; 2010 Jun; 23(6):1529-35. PubMed ID: 20428806
[TBL] [Abstract][Full Text] [Related]
11. Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system.
Yu WD; Ma Y; Flynn G; Muindi JR; Kong RX; Trump DL; Johnson CS
Cell Cycle; 2010 Aug; 9(15):3022-9. PubMed ID: 20699664
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
Zagon IS; Jaglowski JR; Verderame MF; Smith JP; Leure-Dupree AE; McLaughlin PJ
Cancer Chemother Pharmacol; 2005 Nov; 56(5):510-20. PubMed ID: 15947928
[TBL] [Abstract][Full Text] [Related]
13. Synergistic activity of gamma-linolenic acid and cytotoxic drugs against pancreatic adenocarcinoma cell lines.
Whitehouse PA; Cooper AJ; Johnson CD
Pancreatology; 2003; 3(5):367-73; discussion 373-4. PubMed ID: 14526145
[TBL] [Abstract][Full Text] [Related]
14. 5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells.
Halloran CM; Ghaneh P; Shore S; Greenhalf W; Zumstein L; Wilson D; Neoptolemos JP; Costello E
J Gene Med; 2004 May; 6(5):514-25. PubMed ID: 15133762
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment with tamoxifen and a fusicoccin derivative (ISIR-042) to overcome resistance to therapy and to enhance the antitumor activity of 5-fluorouracil and gemcitabine in pancreatic cancer cells.
Miyake T; Honma Y; Urano T; Kato N; Suzumiya J
Int J Oncol; 2015 Jul; 47(1):315-24. PubMed ID: 25936828
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines.
Lanvers-Kaminsky C; Bremer A; Dirksen U; Jürgens H; Boos J
Anticancer Drugs; 2006 Jul; 17(6):657-62. PubMed ID: 16917211
[TBL] [Abstract][Full Text] [Related]
17. Autophagy is needed for the growth of pancreatic adenocarcinoma and has a cytoprotective effect against anticancer drugs.
Hashimoto D; Bläuer M; Hirota M; Ikonen NH; Sand J; Laukkarinen J
Eur J Cancer; 2014 May; 50(7):1382-90. PubMed ID: 24503026
[TBL] [Abstract][Full Text] [Related]
18. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM
J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015
[TBL] [Abstract][Full Text] [Related]
19. Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study.
Pföhler C; Cree IA; Ugurel S; Kuwert C; Haass N; Neuber K; Hengge U; Corrie PG; Zutt M; Tilgen W; Reinhold U
Anticancer Drugs; 2003 Jun; 14(5):337-40. PubMed ID: 12782938
[TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside.
Neale MH; Myatt N; Cree IA; Kurbacher CM; Foss AJ; Hungerford JL; Plowman PN
Br J Cancer; 1999 Mar; 79(9-10):1487-93. PubMed ID: 10188895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
